Overview
| Generic Names: | (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol; DL-oxprenolol; Osprenololo [dcit]; Oxprenololum [inn-latin] |
|---|---|
| Trade Names: | Coretal; Laracor; Slow-pren; Trasacor; Trasicor |
| PharmGKB Accession Id: | PA10284 |
Description
A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety. PubChem (source: Drug Bank)
Indication
Used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety. (source: Drug Bank)
ATC Therapeutic Category
- C07AA:Beta blocking agents, non-selective
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Like other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, oxprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Oxprenolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. (source: Drug Bank)
Pharmacology
Oxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity. Oxprenolol is a lipophilic beta blocker which passes the blood-brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol. Oxprenolol is an potent beta-blocker and should not be administered to asthmatics because it can cause irreversible airway failure and inflammation. (source: Drug Bank)
Food Interactions
Avoid alcohol.
Avoid natural licorice.
Take without regard to meals.
(source:
Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic. (source: Drug Bank)
Absorption
Oral bioavailability is 20-70%. (source: Drug Bank)
Toxicity
Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing. (source: Drug Bank)
Isomeric SMILES Code:
CC(C)NCC(COc1ccccc1OCC=C)O (source: Drug Bank)
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| ADRB1 |
|
(source: Drug Bank) |
| ADRB2 |
|
(source: Drug Bank) |
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| chlorpropamide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| clonidine |
|
Increased hypertension when clonidine stopped (source: Drug Bank) |
| epinephrine |
|
Hypertension, then bradycardia (source: Drug Bank) |
| ergonovine |
|
Ischemia with risk of gangrene (source: Drug Bank) |
| fenoterol |
|
Antagonism (source: Drug Bank) |
| formoterol |
|
Antagonism (source: Drug Bank) |
| glibenclamide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| gliclazide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| glipizide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| ibuprofen |
|
Risk of inhibition of renal prostaglandins (source: Drug Bank) |
| indomethacin |
|
Risk of inhibition of renal prostaglandins (source: Drug Bank) |
| isoproterenol |
|
Antagonism (source: Drug Bank) |
| l-methyldopa |
|
Possible hypertensive crisis (source: Drug Bank) |
| lidocaine |
|
The beta-blocker increases the effect and toxicity of lidocaine (source: Drug Bank) |
| orciprenaline |
|
Antagonism (source: Drug Bank) |
| pirbuterol |
|
Antagonism (source: Drug Bank) |
| piroxicam |
|
Risk of inhibition of renal prostaglandins (source: Drug Bank) |
| prazosin |
|
Risk of hypotension at the beginning of therapy (source: Drug Bank) |
| repaglinide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| salbutamol |
|
Antagonism (source: Drug Bank) |
| salmeterol |
|
Antagonism (source: Drug Bank) |
| terbutaline |
|
Antagonism (source: Drug Bank) |
| tolbutamide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| verapamil |
|
Increased effect of both drugs (source: Drug Bank) |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.